AbbVie's Eczema and Weight-Loss Candidates Show Positive Phase Data
ABBV sits 38% above its 52-week low of $190.75 on light trading volume (0.1× avg).
Summary
AbbVie reported positive Phase 2 data for zumilokibart in moderate-to-severe atopic dermatitis, with all doses showing statistically significant skin clearance and itch reduction versus placebo. Separately, Phase 1 data for ABBV-295, an amylin analog for weight loss, showed dose-dependent body weight reductions of 7.8% to 9.8% over 12-13 weeks with a favorable safety profile. These readouts expand AbbVie's immunology and metabolic pipelines beyond its current blockbusters Skyrizi and Rinvoq. The stock is trading near its 52-week high, reflecting strong investor confidence. Next catalysts include further Phase 3 initiation for zumilokibart and additional ABBV-295 data.
At the time of this announcement, ABBV was trading at $263.83 on NYSE in the Life Sciences sector, with a market capitalization of approximately $466.2B. The 52-week trading range was $190.75 to $269.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.